Enanta Pharmaceuticals, Inc.
ENTANASDAQHealthcare● Active
$11.07
$-0.21(-1.86%)
Market Cap$257008172
P/E Ratio—
52W High$17.15
52W Low$6.435
Enanta Pharmaceuticals, Inc. (ENTA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ENTA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $65.32M | $67.64M | $79.20M | $86.16M | $97.07M |
| Cost of Revenue | $4.59M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $60.74M | $67.64M | $79.20M | $86.16M | $97.07M |
| Gross Margin %(computed) | 92.98% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $106.74M | $131.48M | $163.52M | $164.52M | $174.11M |
| G&A Expenses | $43.93M | $57.85M | $52.89M | $45.48M | $32.54M |
| Total Operating Expenses | $146.09M | $189.33M | $216.41M | $210.00M | $206.65M |
| Operating Income | ($85.35M) | ($121.69M) | ($137.21M) | ($123.84M) | ($109.57M) |
| Operating Margin %(computed) | -130.65% | -179.92% | -173.23% | -143.74% | -112.88% |
| Interest Income | $9.48M | $14.77M | $11.36M | $1.57M | $2.02M |
| Interest Expense | $7.68M | $10.94M | $5.15M | $0.00M | $0.00M |
| Income Before Tax | ($83.55M) | ($117.79M) | ($131.00M) | ($122.19M) | ($107.58M) |
| Income Tax Expense | ($1.66M) | ($1.74M) | $2.82M | ($0.43M) | ($28.58M) |
| Net Income | ($81.89M) | ($116.05M) | ($133.82M) | ($121.75M) | ($79.00M) |
| Net Margin %(computed) | -125.36% | -171.58% | -168.95% | -141.31% | -81.38% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 |
| Wtd Avg Shares | 21.34M | 21.16M | 20.97M | 20.60M | 20.17M |
| EBITDA | ($70.78M) | ($104.51M) | ($123.48M) | ($119.22M) | ($104.25M) |
| EBITDA Margin %(computed) | -108.35% | -154.52% | -155.90% | -138.36% | -107.39% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Enanta Pharmaceuticals, Inc. data
About Enanta Pharmaceuticals, Inc. (ENTA) Income Statement
Enanta Pharmaceuticals, Inc. (ENTA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ENTA reported revenue of $0.07B, gross profit of $0.06B (gross margin 92.98%), and net income of ($0.08B) — a net profit margin of -125.36%.
Frequently asked questions
ENTA · 4 questionsEnanta Pharmaceuticals, Inc. (ENTA) reported revenue of $0.07B for 2025, down 3.4% year-over-year.
ENTA revenueENTA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08